autoimmune disease

Biotech startup Repertoire adds $189M to expand array of immune medicines
Biotech startup Repertoire adds $189M to expand array of immune medicines
MedCity News
Repertoire Immune Medicines
autoimmune disease
infectious diseases
Flag link:
Genmab could spin out autoimmune disease unit, says CEO
Genmab could spin out autoimmune disease unit, says CEO
Pharmaforum
Genmab
autoimmune disease
spinoffs
Flag link:
Lilly wagers almost $1B on Rigel's drugs for immune and nervous systems
Lilly wagers almost $1B on Rigel's drugs for immune and nervous systems
BioPharma Dive
Eli Lilly
Rigel Pharmaceuticals
autoimmune disease
inflammatory disease
Flag link:
Roche chucks out phase 3 ipatasertib combo tests, midstage IL-33 asthma, BTKi arthritis trials in Q4 clear-out
Roche chucks out phase 3 ipatasertib combo tests, midstage IL-33 asthma, BTKi arthritis trials in Q4 clear-out
Fierce Biotech
Roche
earnings
cancer
autoimmune disease
drug development
Flag link:
Horizon inks $3B deal to buy AstraZeneca spinout Viela for autoimmune drugs
Horizon inks $3B deal to buy AstraZeneca spinout Viela for autoimmune drugs
Fierce Biotech
Horizon Therapeutics
AstraZeneca
Viela Bio
autoimmune disease
R&D
M&A
Flag link:
Amgen ponies up $240M for Michigan discovery outfit's dendritic cell-based molecules for autoimmune disorders
Amgen ponies up $240M for Michigan discovery outfit's dendritic cell-based molecules for autoimmune disorders
Endpoints
Amgen
autoimmune disease
Evoq Therapeutics
Flag link:
Pandion unveils new data to back up strategy of activating PD-1 to treat autoimmune diseases
Pandion unveils new data to back up strategy of activating PD-1 to treat autoimmune diseases
Fierce Biotech
Pandion
autoimmune disease
FOCIS
Flag link:
Pfizer's Unheralded Franchise That's Worth Billions of Dollars
Pfizer's Unheralded Franchise That's Worth Billions of Dollars
Motley Fool
Pfizer
biosimilars
Humira
Inflectra
Remsima
Remicade
autoimmune disease
JNJ
Flag link:
Pandion Raises $80 Million Series B to Advance Autoimmune Therapies
Pandion Raises $80 Million Series B to Advance Autoimmune Therapies
BioSpace
Pandion Therapeutics
autoimmune disease
Flag link:
Lilly pays Sitryx $50M upfront for preclinical autoimmune assets
Lilly pays Sitryx $50M upfront for preclinical autoimmune assets
Fierce Biotech
Eli Lilly
Sitryx
autoimmune disease
Flag link:
Thymus atlas could spark new treatments for cancer, autoimmune disease
Thymus atlas could spark new treatments for cancer, autoimmune disease
Fierce Biotech
thymus
autoimmune disease
cancer
Flag link:
Sonoma Bio Launches With $40M to Take Cell Therapy Beyond Cancer
Sonoma Bio Launches With $40M to Take Cell Therapy Beyond Cancer
Xconomy
Sonoma Biosciences
cell therapy
autoimmune disease
Flag link:
5 years of biosimilars in the US: what have we learned?
5 years of biosimilars in the US: what have we learned?
Pharmaforum
biosimilars
cancer
autoimmune disease
Flag link:
Adrangi mounts short attack on 'worthless' drugs of Sanofi ally
Adrangi mounts short attack on 'worthless' drugs of Sanofi ally
Fierce Biotech
Principia Biopharma
Sanofi
autoimmune disease
Kerrisdale Capital
Flag link:
2 Biotechs Battling Immune Diseases
2 Biotechs Battling Immune Diseases
Motley Fool
Rigel Pharmaceuticals
Momenta Pharmaceuticals
autoimmune disease
biologics
small molecule drugs
Flag link:
After closing one of China's biggest-ever raises, I-Mab Biopharma nabs $104M Nasdaq IPO
After closing one of China's biggest-ever raises, I-Mab Biopharma nabs $104M Nasdaq IPO
Fierce Biotech
IPOs
China
NASDAQ
I-Mab Biopharma
autoimmune disease
cancer
Flag link:
Upcoming events – Wave takes on Huntington's and Argenx goes subcutaneous
Upcoming events – Wave takes on Huntington's and Argenx goes subcutaneous
EP Vantage
Wave Life Sciences
WVE-120101
Huntington's disease
Argenx
efgartigimod
autoimmune disease
Flag link:
J&J's Remicade losing ground in Quebec health plan despite court victory
J&J's Remicade losing ground in Quebec health plan despite court victory
Yahoo/Reuters
JNJ
Canada
Quebec
Remicade
autoimmune disease
Flag link:
Pandion, Astellas sign $900m deal for pancreas-targeted immunomodulators
Pandion, Astellas sign $900m deal for pancreas-targeted immunomodulators
Pharmaceutical Business Review
Astellas
Pandion Therapeutics
immunomodulators
autoimmune disease
Pancreas
Flag link:
CAR-T cells as 'bait' show promise in autoimmune disease
CAR-T cells as 'bait' show promise in autoimmune disease
Fierce Biotech
CAR-T
autoimmune disease
Flag link:

Pages